

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma (ID: 1768)

Tweetorial #2 References

Tweet 6

Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *Journal of Clinical Oncology*. 2005;23:21. 10.1200/JCO.2005.07.757 *Journal of Clinical Oncology* 23, no. 21 (July 20, 2005) 4602-4608.

Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *Journal of Clinical Oncology*. 2008;18:17. 10.1200/JCO.2000.18.17.3068 *Journal of Clinical Oncology* 18, no. 17 (September 17, 2000) 3068-3077.

De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. *Journal of Clinical Oncology*. 2011;30:2. 10.1200/JCO.2011.37.3571 *Journal of Clinical Oncology* 30, no. 2 (January 10, 2012) 191-199.

Tweet 8

Jiang DM, Gupta S, Kitchlu AMM, et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. *Nature Reviews Urology*. 2021;18:104-114. <https://doi.org/10.1038/s41585-020-00404-6>

Tweet 10

Suzman DL, Agrawal S, Ning Y, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. *The Oncologist*. 2018;24:4. <https://doi.org/10.1634/theoncologist.2018-0084>

Tweet 11

Galsky MD, Ariba JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *The Lancet*. 2020;395:10236. [https://doi.org/10.1016/S0140-6736\(20\)30230-0](https://doi.org/10.1016/S0140-6736(20)30230-0)

Tweet 12

Tewari A. ESMO Virtual Congress 2020: Pembrolizumab Combined with Chemotherapy vs Chemotherapy Alone as First-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-361. Presented at the European Society for Medical Oncology Virtual Congress, ESMO Virtual Congress 2020; September 18-21 2020; Virtual.

Tweet 13

Powles T, van der Heijden M, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *The Lancet Oncology*. 2020;21:12. [https://doi.org/10.1016/S1470-2045\(20\)30541-6](https://doi.org/10.1016/S1470-2045(20)30541-6)

Glossary

%, percentage
b/f, before
CI, confidence interval
CIS, carcinoma in situ
CrCl, creatine clearance
ctcae, common terminology criteria for adverse events
Dz, disease
ECOG, Eastern Cooperative Oncology Group
ICI, intracavernosal injection
Itt, intention to treat
mL/min, milliliters per minute
ORR, objective response rate
OS, overall survival
PD-L1, Programmed death-ligand 1
PFS, pelvic floor stimulation
Pt, patient
RCT, randomized controlled trial
RR, risk ratio
SOC, CIS-based chemo
Tx, treatment
UC, urologic cancer
Y, year
YO, year old